$107.72▴ 1.16%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Halozyme Therapeutics, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days3 articles
1 bullish1 neutral1 bearish
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Biotech ETFs to Buy as Cancer Drug Breakthroughs AccelerateAcumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?